MPR Weekly Dose

MPR Weekly Dose 77 - Updated mask guidance; Janssen vaccine resumption; Steroid therapy in COVID-19; Novel MDD gains Priority Review; Scabies treatment; Stroke rehabilitation device

Apr 30, 2021

New guidelines on mask use; J&J vaccine update; Novel major depressive disorder treatment gains Priority Review; A scabies topical suspension; And a device to help stroke rehabilitation.

MPR Weekly Dose 76 - Bamlanivimab emergency use changes; Janssen vaccine facilities; Molnupiravir trial halted; New contraceptive approved; Ragweed pollen allergy treatment

Apr 23, 2021

The FDA revoke Emergency Use Authorization for bamlanivimab; Issues identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID-19 therapy; A new contraceptive is approved; And Ragwitek has approval expanded.

MPR Weekly Dose 75 - Janssen vaccine on pause; Antibody therapy guidance; Remote mifepristone dispensing; Xolair self-administration; And a new AI colonoscopy system

Apr 16, 2021

The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatments; The FDA changes in-person mifepristone dispensing; Xolair prefilled syringe approved for self-administration in select patients; And the AI world comes to colonoscopies.

MPR Weekly Dose 74 - Updated travel guidance; Six month vaccine efficacy data; Increased Moderna doses per vial; New ADHD treatment; And a safety communication for lamotrigine

Apr 9, 2021

Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding the potential increased...